BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

474 related articles for article (PubMed ID: 30276787)

  • 21. Recent epidemiology of patients with gastro-entero-pancreatic neuroendocrine neoplasms (GEP-NEN) in Japan: a population-based study.
    Masui T; Ito T; Komoto I; Uemoto S;
    BMC Cancer; 2020 Nov; 20(1):1104. PubMed ID: 33189127
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Combined visual and quantitative assessment of somatostatin receptor scintigraphy for staging and restaging of neuroendocrine tumors.
    Ueki Y; Otsuka H; Otani T; Kasai R; Otomi Y; Ikemitsu D; Azane S; Kunikane Y; Bando T; Matsuda N; Okada Y; Takayama T; Harada M
    Jpn J Radiol; 2024 May; 42(5):519-535. PubMed ID: 38345724
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Clinical application of
    Xu J; Li Y; Xu X; Zhang J; Zhang Y; Yu X; Huang D
    Ann Nucl Med; 2018 Aug; 32(7):446-452. PubMed ID: 29926342
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Prediction and diagnosis of bone metastases in well-differentiated gastro-entero-pancreatic endocrine cancer: a prospective comparison of whole body magnetic resonance imaging and somatostatin receptor scintigraphy.
    Leboulleux S; Dromain C; Vataire AL; Malka D; Aupérin A; Lumbroso J; Duvillard P; Elias D; Hartl DM; De Baere T; Guigay J; Schlumberger M; Ducreux M; Baudin E
    J Clin Endocrinol Metab; 2008 Aug; 93(8):3021-8. PubMed ID: 18522978
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Incremental value of
    Trogrlic M; Težak S
    Nuklearmedizin; 2017 Jun; 56(3):97-107. PubMed ID: 28164207
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Significance of a Single-Time-Point Somatostatin Receptor SPECT/Multiphase CT Protocol in the Diagnostic Work-up of Gastroenteropancreatic Neuroendocrine Neoplasms.
    Ruf J; von Wedel F; Furth C; Denecke T; Stelter L; Steffen IG; Schütte K; Arend J; Ulrich G; Klose S; Bornschein J; Apostolova I; Amthauer H
    J Nucl Med; 2016 Feb; 57(2):180-5. PubMed ID: 26609177
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Comparison of [
    Chen D; Yang S; Chen J; Li T; Liu Y; Zhao X; Zhang T; Xu M; Wang H; Zhao K; Su X
    Eur J Nucl Med Mol Imaging; 2023 Jul; 50(8):2420-2431. PubMed ID: 36971805
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Peptide Receptor Radionuclide Therapy in Grade 3 Neuroendocrine Neoplasms: Safety and Survival Analysis in 69 Patients.
    Zhang J; Kulkarni HR; Singh A; Niepsch K; Müller D; Baum RP
    J Nucl Med; 2019 Mar; 60(3):377-385. PubMed ID: 30115686
    [TBL] [Abstract][Full Text] [Related]  

  • 29. 68Ga-DOTA-Tyr3-octreotide PET in neuroendocrine tumors: comparison with somatostatin receptor scintigraphy and CT.
    Gabriel M; Decristoforo C; Kendler D; Dobrozemsky G; Heute D; Uprimny C; Kovacs P; Von Guggenberg E; Bale R; Virgolini IJ
    J Nucl Med; 2007 Apr; 48(4):508-18. PubMed ID: 17401086
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Imaging of neuroendocrine tumors: accuracy of helical CT versus SRS.
    Kumbasar B; Kamel IR; Tekes A; Eng J; Fishman EK; Wahl RL
    Abdom Imaging; 2004; 29(6):696-702. PubMed ID: 15162235
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Detection of somatostatin receptor subtypes 2 and 5 by somatostatin receptor scintigraphy and immunohistochemistry: clinical implications in the diagnostic and therapeutic management of gastroenteropancreatic neuroendocrine tumors.
    Sclafani F; Carnaghi C; Di Tommaso L; Rodari M; Destro A; Rimassa L; Giordano L; Chiti A; Roncalli M; Santoro A
    Tumori; 2011; 97(5):620-8. PubMed ID: 22158494
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Diagnosis of neuroendocrine tumours by retrospective image fusion: is there a benefit?
    Amthauer H; Ruf J; Böhmig M; Lopez-Hänninen E; Rohlfing T; Wernecke KD; Plöckinger U; Gutberlet M; Lemke AJ; Steinmüller T; Wiedenmann B; Felix R
    Eur J Nucl Med Mol Imaging; 2004 Mar; 31(3):342-8. PubMed ID: 14652697
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Clinical impact of somatostatin receptor scintigraphy in the management of patients with neuroendocrine gastroenteropancreatic tumors.
    Lebtahi R; Cadiot G; Sarda L; Daou D; Faraggi M; Petegnief Y; Mignon M; le Guludec D
    J Nucl Med; 1997 Jun; 38(6):853-8. PubMed ID: 9189129
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Clinicopathological features and prognosis of gastroenteropancreatic neuroendocrine neoplasms in a Chinese population: a large, retrospective single-centre study.
    Zhang M; Zhao P; Shi X; Zhao A; Zhang L; Zhou L
    BMC Endocr Disord; 2017 Jul; 17(1):39. PubMed ID: 28705205
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Peptide receptor radionuclide therapy in gastroenteropancreatic NEN G3: a multicenter cohort study.
    Carlsen EA; Fazio N; Granberg D; Grozinsky-Glasberg S; Ahmadzadehfar H; Grana CM; Zandee WT; Cwikla J; Walter MA; Oturai PS; Rinke A; Weaver A; Frilling A; Gritti S; Arveschoug AK; Meirovitz A; Knigge U; Sorbye H
    Endocr Relat Cancer; 2019 Feb; 26(2):227-239. PubMed ID: 30540557
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Clinical usefulness of Somatostatin Receptor Scintigraphy in the Diagnosis of Neuroendocrine Neoplasms.
    Inaba Y; Hijioka S; Iwama I; Asai T; Miyamura H; Chatani S; Hasegawa T; Murata S; Kato M; Sato Y; Yamaura H; Onaya H; Shimizu J; Hara K
    Asia Ocean J Nucl Med Biol; 2022; 10(1):1-13. PubMed ID: 35083344
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Neuroendocrine Tumor Heterogeneity Adds Uncertainty to the World Health Organization 2010 Classification: Real-World Data from the Spanish Tumor Registry (R-GETNE).
    Nuñez-Valdovinos B; Carmona-Bayonas A; Jimenez-Fonseca P; Capdevila J; Castaño-Pascual Á; Benavent M; Pi Barrio JJ; Teule A; Alonso V; Custodio A; Marazuela M; Segura Á; Beguiristain A; Llanos M; Martinez Del Prado MP; Diaz-Perez JA; Castellano D; Sevilla I; Lopez C; Alonso T; Garcia-Carbonero R
    Oncologist; 2018 Apr; 23(4):422-432. PubMed ID: 29330208
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Imaging of neuroendocrine gastro-entero-pancreatic tumours using radiolabelled somatostatin analogues.
    Chiti A; van Graafeiland BJ; Savelli G; Ferrari L; Seregni E; Castellani MR; Bombardieri E
    Ital J Gastroenterol Hepatol; 1999 Oct; 31 Suppl 2():S190-4. PubMed ID: 10604128
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The clinical value of scintigraphy of neuroendocrine tumors using (99m)Tc-HYNIC-TOC.
    Artiko V; Sobic-Saranovic D; Pavlovic S; Petrovic M; Zuvela M; Antic A; Matic S; Odalovic S; Petrovic N; Milovanovic A; Obradovic V
    J BUON; 2012; 17(3):537-42. PubMed ID: 23033296
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The association of intra-therapeutic heterogeneity of somatostatin receptor expression with morphological treatment response in patients undergoing PRRT with [177Lu]-DOTATATE.
    Wetz C; Genseke P; Apostolova I; Furth C; Ghazzawi S; Rogasch JMM; Schatka I; Kreissl MC; Hofheinz F; Grosser OS; Amthauer H
    PLoS One; 2019; 14(5):e0216781. PubMed ID: 31091247
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 24.